On the 15th, Huya bio International (Huya), a leading enterprise in the global joint development of China's original new biomedicine, signed an exclusive patent license with Fudan University for new immune tumor candidate drugs discovered by Fudan researchers. Therefore, Huya can have the global patent rights and interests of the immune tumor candidate drug except China.
It is reported that the drug is a new inhibitor of indoleamine-2,3-dioxygenase (IDO), which has been developed by the research group of Professor Yang Qing, Academy of life sciences, Fudan University for more than ten years. It is reported that Ido is an enzyme containing heme, which is widely distributed in many tissues and cells of human and animals. At present, Ido has been proved to be an important drug discovery target. As a drug with new drug target and new mechanism, Ido inhibitor can be used to treat a variety of major diseases such as tumor, Alzheimer's disease, depression, cataract and so on.
Due to the low inhibitory effect of existing Ido inhibitors, there is no Ido inhibitor drug available at present. Two compounds have entered clinical trials abroad: nlg919 compound of new link genetics and incb024360 compound of Incyte. Compared with the above two compounds, Ido compounds developed by Yang Qing's research group are more groundbreaking.
Huya disclosed that it plans to enter the clinical trial of this product in advance to cooperate with the sustainable development of hbi-8000. Hbi-8000 is a new histone deacetylase inhibitor developed by Huya, which has shown its unique immunomodulatory properties.
"These new Ido compounds will greatly expand the immunooncology platform and can be combined with other drugs to solve the immunorestrictive treatment caused by T-cell inhibition test," said Dr. Bob goodenow, CBO of Huya.
Professor Jin Li, vice president of Fudan University and academician of the Chinese Academy of Sciences, said on the same day, "I am very glad to cooperate with Huya on the project. Their professional knowledge will help to show the greatest value of Fudan's world-class research results on the world stage".
Huya said that it was optimistic about China's innovation ability 10 years ago and believed that China would have more innovation in the future.
